Pharmacology Division, University Institute of Pharmaceutical Sciences, UGC-CAS, Panjab University, Chandigarh 160014, India; Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (IIT-B.H.U.), Varanasi 221005, Uttar Pradesh, India.
Pharmacology Division, University Institute of Pharmaceutical Sciences, UGC-CAS, Panjab University, Chandigarh 160014, India.
Pharmacol Biochem Behav. 2019 Oct;185:172763. doi: 10.1016/j.pbb.2019.172763. Epub 2019 Aug 22.
Pharmacotherapy and cognitive behavioral therapy, both fail to treat post-traumatic stress disorder (PTSD) in a considerable number of populations. The persistence of traumatic memories and deficit in extinction contributes to the failure of exposure therapy in PTSD. With the objective to enhance the outcomes of exposure therapy by targeting the extinction window using pharmacological agents in PTSD, the present study was aimed to explore the effect of piracetam, risperidone and their combinations in experimentally-induced PTSD-like phenotype in rats. Male SD rats were exposed to single prolonged stress model (SPS) for induction of PTSD-like behavioral changes. Piracetam, risperidone and their combination were used as therapeutic interventions while sertraline was used as a standard treatment for 14 days along with extinction training. Induction of PTSD-like behaviors were assessed in behavioral tests such as fear conditioning, elevated plus maze, social interaction test, and the marble burying test. Neurotransmitters (dopamine and serotonin and their metabolites), BDNF, proinflammatory cytokines (TNF-α, IL-6), caspase-3, and markers for oxidative stress were assessed in the hippocampus and cortex while corticosterone and nitrite levels were estimated in plasma. Our result indicated that the SPS paradigm efficiently induced PTSD-like phenotype in rats. Risperidone and piracetam were found to be effective alone, while their high dose combination, produced potentiating effect in reversing the extinction deficit, behavioral alterations, altered cortical and hippocampal BDNF, IL-6, TNF-α, caspase-3, oxidative stress markers, and neurotransmitter levels. Plasma corticosterone and nitrite levels were also found to be reversed in the combination treated groups. Our preliminary study suggests that piracetam, risperidone and their combination restored the physiological cascades in cortex and hippocampus along with successful suppression of fear memory and a symptom cluster of PTSD-like phenotype in rats. Hence they could be used as an effective adjunct to enhance the outcome of exposure therapy for the management of PTSD.
药物治疗和认知行为疗法都未能在相当数量的人群中治疗创伤后应激障碍(PTSD)。创伤记忆的持续存在和消退缺陷导致 PTSD 暴露疗法的失败。为了通过在 PTSD 中使用药物靶向消退窗口来增强暴露疗法的效果,本研究旨在探索吡拉西坦、利培酮及其组合在大鼠实验性 PTSD 样表型中的作用。雄性 SD 大鼠接受单次延长应激模型(SPS)暴露以诱导 PTSD 样行为改变。吡拉西坦、利培酮及其组合作为治疗干预措施,舍曲林作为标准治疗,与消退训练一起使用 14 天。在行为测试中评估 PTSD 样行为,如恐惧条件反射、高架十字迷宫、社会互动测试和大理石埋藏测试。在海马体和皮质中评估神经递质(多巴胺和 5-羟色胺及其代谢物)、BDNF、促炎细胞因子(TNF-α、IL-6)、caspase-3 和氧化应激标志物,同时评估血浆中的皮质酮和亚硝酸盐水平。我们的结果表明,SPS 范式有效地诱导了大鼠 PTSD 样表型。发现利培酮和吡拉西坦单独使用有效,而它们的高剂量组合在逆转消退缺陷、行为改变、改变皮质和海马 BDNF、IL-6、TNF-α、caspase-3、氧化应激标志物和神经递质水平方面具有增效作用。组合治疗组的血浆皮质酮和亚硝酸盐水平也被发现得到逆转。我们的初步研究表明,吡拉西坦、利培酮及其组合恢复了皮质和海马体的生理级联反应,成功抑制了恐惧记忆和大鼠 PTSD 样表型的症状群。因此,它们可以作为增强暴露疗法治疗 PTSD 效果的有效辅助手段。